Neurocrine Biosciences (NBIX) 39.71 $NBIX
Let Neurocrine Biosciences Cool Off - Cramer's Lightning Round (3/30/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Tue Mar 31, 5:31AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, March 30. Bullish Calls: Fiat Chrysler (NYSE: FCAU ): "I like Fiat Chrysler. I think it's in a good situation. I think Fiat is better right now, but...
70.87 (-0.27), PGNX: 5.98 (+0.16), AA: 12.92 (-0.04), TAC: 9.30 (+0.07), NBIX: 39.71 (-1.82), CMI: 138.64 (-1.50), ED: 61.00 (+0.21), GM: 37.50 (-0.18), FCAU: 16.31 (-0.24), WDC: 91.01 (-1.92)
'Mad Money' Lightning Round: Alcoa Is Doing Everything Right
at The Street - Tue Mar 31, 5:00AM CDT
Cramer says to wait on Neurocrine Biosciences and Cummins and lighten up on Western Digital.
70.87 (-0.27), AEP: 56.25 (-0.33), TAC: 9.30 (+0.07), AA: 12.92 (-0.04), NBIX: 39.71 (-1.82), CMI: 138.64 (-1.50), ED: 61.00 (+0.21), FCAU: 16.31 (-0.24), WDC: 91.01 (-1.92)
Jim Cramer's 'Mad Money' Recap: Good Headlines Make All the Difference
at The Street - Mon Mar 30, 7:06PM CDT
It's nice to see the flow of money has reversed from last week's relentless selloff, Cramer says.
70.87 (-0.27), HRS: 78.76 (+1.13), TSLA: 188.77 (-1.80), RH: 99.19 (+0.12), AMZN: 372.10 (-2.49), CTRX: 59.54 (-0.29), BMRN: 124.62 (-4.51), SWKS: 98.29 (-1.84), NKE: 100.33 (-0.56), ED: 61.00 (+0.21), FCAU: 16.31 (-0.24), WDC: 91.01 (-1.92), SLB: 83.44 (-1.04), LULU: 64.02 (-0.81), NFLX: 416.69 (-5.88), AEP: 56.25 (-0.33), XLS: 24.37 (+0.10), TAC: 9.30 (+0.07), AA: 12.92 (-0.04), NBIX: 39.71 (-1.82), CMI: 138.64 (-1.50), ADI: 63.00 (-1.81), HZNP: 25.97 (+0.19), RCPT: 164.89 (+4.84), TEVA: 62.30 (-0.22)
What To Make Of Neurocrine's Recent Insider Selling
Clinically Sound Investor - at Seeking Alpha - Thu Mar 26, 8:41AM CDT
NBIX: 39.71 (-1.82)
Early Briefing on Biotech Industry Stocks -- ARIAD Pharma, Array BioPharma, Rexahn Pharma, Inotek Pharma, and Neurocrine Biosciences
PR Newswire - Tue Mar 03, 7:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
RNN: 0.73 (+0.01), NBIX: 39.71 (-1.82), ITEK: 5.42 (+0.23), ARIA: 8.24 (-0.32), ARRY: 7.37 (-0.17)
Polycystic Ovarian Syndrome Therapeutics Pipeline Review 2015
M2 - Mon Mar 02, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/wx3bdj/polycystic) has announced the addition of the "Polycystic Ovarian Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Crinetics Pharmaceuticals, Inc. - EffRx Pharmaceuticals S.A. - Euroscreen S.A. - Merck KGaA - Neurocrine Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/wx3bdj/polycystic
NBIX: 39.71 (-1.82), AZN: 68.43 (-1.51)
Neurocrine Biosciences: A More Solid Investment After Recent Secondary
Clinically Sound Investor - at Seeking Alpha - Sat Feb 21, 10:12AM CST
NBIX: 39.71 (-1.82)
Neurocrine Bio initiates equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 3:46PM CST
NBIX: 39.71 (-1.82)
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
PR Newswire - Thu Feb 19, 6:00AM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of its underwritten public offering of 6,944,000 shares of its common stock at a price to the public of $36.00 per share. The gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Neurocrine, are expected to be approximately $250 million. The offering is expected to close on or about February 24, 2015, subject to customary closing conditions. Neurocrine anticipates using the net proceeds from the offering to fund its research and development efforts, to prepare for commercialization efforts and for general corporate purposes, including working capital.
NBIX: 39.71 (-1.82), JPM: 60.58 (-0.38)
Recent Developments in the Healthcare Sector: Special Research on Neurocrine Biosciences, Novavax, NPS Pharma, Osiris Therapeutics, and OXiGENE
PR Newswire - Wed Feb 18, 8:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
OXGN: 1.46 (+0.02), NBIX: 39.71 (-1.82), NVAX: 8.27 (-0.37), OSIR: 17.58 (-0.07), NPSP: 45.97 (+0.01)
Neurocrine Biosciences plans public offering of USD225m common shares
M2 - Wed Feb 18, 6:29AM CST
Pharmaceuticals company Neurocrine Biosciences (NasdaqGS:NBIX) said on Tuesday that it expects aggregate proceeds of approximately USD225m from its public offering of common stock.
NBIX: 39.71 (-1.82)
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of $225 Million of Common Stock
PR Newswire - Tue Feb 17, 3:08PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $225 million. In connection with this offering, Neurocrine will also grant to the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold. J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers for this offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Neurocrine anticipates using the net proceeds from the offering to fund its research and development efforts, to prepare for commercialization efforts and for general corporate purposes, including working capital.
NBIX: 39.71 (-1.82), JPM: 60.58 (-0.38), DB: 34.73 (-0.24)
Shares of NBIX Up 103.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 10, 9:08AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 4 months, Neurocrine Biosciences has returned 103.82% as of today's recent price of $34.40.
NBIX: 39.71 (-1.82)
Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 10:58PM CST
NBIX: 39.71 (-1.82)
Neurocrine reports 4Q loss
Automated Insights - Mon Feb 09, 3:21PM CST
SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Monday reported a loss of $19.4 million in its fourth quarter.
NBIX: 39.71 (-1.82)
Neurocrine Biosciences misses by $0.02
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:06PM CST
NBIX: 39.71 (-1.82)
Neurocrine Biosciences Reports Year-End 2014 Results and Provides Investor Update for 2015
PR Newswire - Mon Feb 09, 3:01PM CST
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter and year ended December 31, 2014.
NBIX: 39.71 (-1.82)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Feb 08, 4:35PM CST
CCK: 54.02 (+0.35), MXL: 8.13 (+0.04), TDW: 19.14 (-0.37), MOH: 67.29 (+0.99), DAC: 6.51 (+0.02), PRI: 50.90 (-0.25), ICUI: 93.14 (+2.06), NEWP: 19.06 (-0.29), CSC: 65.28 (-1.17), GSM: 18.92 (-0.04), QLYS: 46.48 (-0.22), AMAG: 54.66 (-1.52), AMKR: 8.83 (-0.06), NTES: 105.30 (+0.28), IPHI: 17.83 (-0.39), GIG: 1.21 (+0.07), ALSN: 31.94 (+0.08), KS: 32.84 (+0.34), SSNI: 8.94 (-0.22), CMP: 93.21 (-0.05), COUP: 11.74 (+0.17), MRH: 38.44 (+0.29), NBIX: 39.71 (-1.82), MODN: 11.96 (+0.04), RLD: 12.79 (+0.36), DNB: 128.36 (-0.82), WCN: 48.14 (+0.05), MCC: 9.15 (-0.11), CRK: 3.57 (+0.09), OTTR: 32.17 (-0.11), MERU: 1.44 (-0.01)
Neurocrine Biosciences to Present at the 2015 Leerink Global Healthcare Conference
PR Newswire - Wed Feb 04, 12:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the 2015 Leerink Global Healthcare Conference in New York City.
NBIX: 39.71 (-1.82)
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2014 Results
PR Newswire - Mon Feb 02, 12:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2014 results after the Nasdaq market closes on Monday, February 9, 2015. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Monday afternoon, February 9, 2015 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 39.71 (-1.82)
Let Neurocrine Biosciences Cool Off - Cramer's Lightning Round (3/30/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Tue Mar 31, 5:31AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, March 30. Bullish Calls: Fiat Chrysler (NYSE: FCAU ): "I like Fiat Chrysler. I think it's in a good situation. I think Fiat is better right now, but...
70.87 (-0.27), PGNX: 5.98 (+0.16), AA: 12.92 (-0.04), TAC: 9.30 (+0.07), NBIX: 39.71 (-1.82), CMI: 138.64 (-1.50), ED: 61.00 (+0.21), GM: 37.50 (-0.18), FCAU: 16.31 (-0.24), WDC: 91.01 (-1.92) 'Mad Money' Lightning Round: Alcoa Is Doing Everything Right
at The Street - Tue Mar 31, 5:00AM CDT
Cramer says to wait on Neurocrine Biosciences and Cummins and lighten up on Western Digital.
70.87 (-0.27), AEP: 56.25 (-0.33), TAC: 9.30 (+0.07), AA: 12.92 (-0.04), NBIX: 39.71 (-1.82), CMI: 138.64 (-1.50), ED: 61.00 (+0.21), FCAU: 16.31 (-0.24), WDC: 91.01 (-1.92) Jim Cramer's 'Mad Money' Recap: Good Headlines Make All the Difference
at The Street - Mon Mar 30, 7:06PM CDT
It's nice to see the flow of money has reversed from last week's relentless selloff, Cramer says.
70.87 (-0.27), HRS: 78.76 (+1.13), TSLA: 188.77 (-1.80), RH: 99.19 (+0.12), AMZN: 372.10 (-2.49), CTRX: 59.54 (-0.29), BMRN: 124.62 (-4.51), SWKS: 98.29 (-1.84), NKE: 100.33 (-0.56), ED: 61.00 (+0.21), FCAU: 16.31 (-0.24), WDC: 91.01 (-1.92), SLB: 83.44 (-1.04), LULU: 64.02 (-0.81), NFLX: 416.69 (-5.88), AEP: 56.25 (-0.33), XLS: 24.37 (+0.10), TAC: 9.30 (+0.07), AA: 12.92 (-0.04), NBIX: 39.71 (-1.82), CMI: 138.64 (-1.50), ADI: 63.00 (-1.81), HZNP: 25.97 (+0.19), RCPT: 164.89 (+4.84), TEVA: 62.30 (-0.22) What To Make Of Neurocrine's Recent Insider Selling
Clinically Sound Investor - at Seeking Alpha - Thu Mar 26, 8:41AM CDT
NBIX: 39.71 (-1.82)
Early Briefing on Biotech Industry Stocks -- ARIAD Pharma, Array BioPharma, Rexahn Pharma, Inotek Pharma, and Neurocrine Biosciences
PR Newswire - Tue Mar 03, 7:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
RNN: 0.73 (+0.01), NBIX: 39.71 (-1.82), ITEK: 5.42 (+0.23), ARIA: 8.24 (-0.32), ARRY: 7.37 (-0.17)
Polycystic Ovarian Syndrome Therapeutics Pipeline Review 2015
M2 - Mon Mar 02, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/wx3bdj/polycystic) has announced the addition of the "Polycystic Ovarian Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Crinetics Pharmaceuticals, Inc. - EffRx Pharmaceuticals S.A. - Euroscreen S.A. - Merck KGaA - Neurocrine Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/wx3bdj/polycystic
NBIX: 39.71 (-1.82), AZN: 68.43 (-1.51)
Neurocrine Biosciences: A More Solid Investment After Recent Secondary
Clinically Sound Investor - at Seeking Alpha - Sat Feb 21, 10:12AM CST
NBIX: 39.71 (-1.82)
Neurocrine Bio initiates equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 3:46PM CST
NBIX: 39.71 (-1.82)
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
PR Newswire - Thu Feb 19, 6:00AM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of its underwritten public offering of 6,944,000 shares of its common stock at a price to the public of $36.00 per share. The gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Neurocrine, are expected to be approximately $250 million. The offering is expected to close on or about February 24, 2015, subject to customary closing conditions. Neurocrine anticipates using the net proceeds from the offering to fund its research and development efforts, to prepare for commercialization efforts and for general corporate purposes, including working capital.
NBIX: 39.71 (-1.82), JPM: 60.58 (-0.38)
Recent Developments in the Healthcare Sector: Special Research on Neurocrine Biosciences, Novavax, NPS Pharma, Osiris Therapeutics, and OXiGENE
PR Newswire - Wed Feb 18, 8:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
OXGN: 1.46 (+0.02), NBIX: 39.71 (-1.82), NVAX: 8.27 (-0.37), OSIR: 17.58 (-0.07), NPSP: 45.97 (+0.01)
Neurocrine Biosciences plans public offering of USD225m common shares
M2 - Wed Feb 18, 6:29AM CST
Pharmaceuticals company Neurocrine Biosciences (NasdaqGS:NBIX) said on Tuesday that it expects aggregate proceeds of approximately USD225m from its public offering of common stock.
NBIX: 39.71 (-1.82)
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of $225 Million of Common Stock
PR Newswire - Tue Feb 17, 3:08PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $225 million. In connection with this offering, Neurocrine will also grant to the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold. J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers for this offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Neurocrine anticipates using the net proceeds from the offering to fund its research and development efforts, to prepare for commercialization efforts and for general corporate purposes, including working capital.
NBIX: 39.71 (-1.82), JPM: 60.58 (-0.38), DB: 34.73 (-0.24)
Shares of NBIX Up 103.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 10, 9:08AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 4 months, Neurocrine Biosciences has returned 103.82% as of today's recent price of $34.40.
NBIX: 39.71 (-1.82)
Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 10:58PM CST
NBIX: 39.71 (-1.82)
Neurocrine reports 4Q loss
Automated Insights - Mon Feb 09, 3:21PM CST
SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Monday reported a loss of $19.4 million in its fourth quarter.
NBIX: 39.71 (-1.82)
Neurocrine Biosciences misses by $0.02
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:06PM CST
NBIX: 39.71 (-1.82)
Neurocrine Biosciences Reports Year-End 2014 Results and Provides Investor Update for 2015
PR Newswire - Mon Feb 09, 3:01PM CST
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter and year ended December 31, 2014.
NBIX: 39.71 (-1.82)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Feb 08, 4:35PM CST
CCK: 54.02 (+0.35), MXL: 8.13 (+0.04), TDW: 19.14 (-0.37), MOH: 67.29 (+0.99), DAC: 6.51 (+0.02), PRI: 50.90 (-0.25), ICUI: 93.14 (+2.06), NEWP: 19.06 (-0.29), CSC: 65.28 (-1.17), GSM: 18.92 (-0.04), QLYS: 46.48 (-0.22), AMAG: 54.66 (-1.52), AMKR: 8.83 (-0.06), NTES: 105.30 (+0.28), IPHI: 17.83 (-0.39), GIG: 1.21 (+0.07), ALSN: 31.94 (+0.08), KS: 32.84 (+0.34), SSNI: 8.94 (-0.22), CMP: 93.21 (-0.05), COUP: 11.74 (+0.17), MRH: 38.44 (+0.29), NBIX: 39.71 (-1.82), MODN: 11.96 (+0.04), RLD: 12.79 (+0.36), DNB: 128.36 (-0.82), WCN: 48.14 (+0.05), MCC: 9.15 (-0.11), CRK: 3.57 (+0.09), OTTR: 32.17 (-0.11), MERU: 1.44 (-0.01)
Neurocrine Biosciences to Present at the 2015 Leerink Global Healthcare Conference
PR Newswire - Wed Feb 04, 12:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the 2015 Leerink Global Healthcare Conference in New York City.
NBIX: 39.71 (-1.82)
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2014 Results
PR Newswire - Mon Feb 02, 12:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2014 results after the Nasdaq market closes on Monday, February 9, 2015. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Monday afternoon, February 9, 2015 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 39.71 (-1.82)
